News | December 06, 2022
Briefs: Natco Pharma & Lupin
Natco Chlorantraniliprole (CTPR) Process does not infringe FMC's Indian Patent 298645.
Natco Chlorantraniliprole (CTPR) Process does not infringe FMC's Indian Patent 298645.
Expanded capacity in Nansha, China will support mid-scale manufacturing to ensure a smooth transition between early-phase and large-scale commercial production
New Lexington, Massachusetts facility to provide customer education and collaboration opportunities
Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule
Diclofenac Sodium Topical Solution USP, 2% w/w has an estimated market size of US $512 million for twelve months ending Sep 2022 according to IQVIA
The joint venture will help both the parties to further develop the high-margin service business
South Asia’s largest exhibition for pharma brought together over 50,000 visitors from across the globe
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
The acquired brands are well established and recognized among doctors and other members of the medical fraternity in Brazil for their reliability, safety, and trustworthiness
Latest innovations feature vendor-neutral solutions to help reduce clinical complexity and enhance operational efficiency
Subscribe To Our Newsletter & Stay Updated
